Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not likely since the company has said repeatedly they're not for sale.
The valuation could explode if Nuplazid can be used for Alzheimer's and Schizophrenia. I'd hold off too.
Two resignations. Whats up with this?
http://biz.yahoo.com/e/151106/acad8-k.html
If he's not raising cash and fast then I will assume "Marina" is his daughter's name.
Not according to their filing in May.
"Item 8.01. Other Events.
The Company has been unsuccessful in its fundraising and partnering/licensing efforts, and does not anticipate being able to raise sufficient capital to continue operations. Consequently, the Board of Directors of the Company has approved an orderly wind down of the Company, including negotiations with its senior secured creditor, Bohemian Investments, LLC."
http://www.sec.gov/Archives/edgar/data/1389870/000143774915009356/ombp20150507_8k.htm
They are out of business friend. They pulled the plug.
On the Shanghai composite monday, ONLY 3% of listed shares traded and it was down 8%. 97% were suspended according to Fox business. Can you imagine how much it would be down if they all traded?
Sept will be a Mother.
OT: Addyi trial user comment.
Sounds like it works fine. Maybe I should buy more PTN.
http://nypost.com/2015/08/20/this-is-what-its-like-to-take-female-viagra/
Supposed to be today but no word yet. Been out all day.
Sounds like a gay bull.
I bet Leon Cooperman is saying the same thing. So much for the insight of a billionaire and his hedge fund.
I like their odds, and that Baker Bros are in it. Good luck to Sprout.
“If the committee green-lights something, the FDA commissioner can still say no, but that happens almost never,” she said. “A green-light from committee means it’s basically in the bag, but you never know.”
The figure is 80% for positive AdComm votes that led to FDA approvals:
Of the 307* products reviewed by 21 committees from 2002 to 2013, 74.6% (229/307) received FDA marketing approval. Committee votes were positive in 80.7% of the cases; of the 78 products that were not approved, 64.1% received negative committee votes.
http://lsconnect.thomsonreuters.com/impact-fda-advisory-committee-voting-fda-approval-decisions-drugs-biologics/
Thanks.
Data, what data? The ph 2a results that are not public knowledge yet?
8-K's are triggered by material events. I'm not sure sale of warrants would do it but would more likely end up in a quarterly report. I should have said 10-K. Sorry for the confusion.
Why bother saying this if you can't provide a reason for the move? Its meaningless blather.
Figure about 2 weeks after this quarter ends which puts it in mid-October.
That won't be known until the next 8-K.
"6.3 million shares in 1 1/2 hours is very good."
Does the fact that its down 7.5% now indicate something important about direction? The volume is distribution!
Sorry, what's "T&S"? That one got by me.
As I said before, I'm a spectator here.
It has to close above support at 1.10 or it will test the next support at .92.
wayne
I keep trying to make the point that we are in a trader's market.
Don't fight it.
"As Jeff Kleintop of LPL Financial writes, the average holding period of a stock has fallen from eight years in the 1960s to around five days today.
Much of this is due to the advent of ETFs and high-frequency trading. But there's little doubt that the average investor is also holding stocks for much shorter periods."
Read more: http://www.businessinsider.com/stock-investor-holding-period-2012-8#ixzz3iW5GFmkk
Uplisting would be huge for them, but they'd need a higher share price and more cash to qualify.
Over the years I've been doing this I've seen a trend to go public prematurely, then companies struggle for funding which hurts their chances at becoming a viable company. I prefer the old way where companies did a Series A, B and maybe C private funding to get them further along before they go public once they have something substantial to attract investors.
Its one more subtle change that's happened over many years. Our father's and grandfather's generation had different investment standards, much more conservative (especially D/E ratios) and would be appalled how much risk we are willing to accept today.
Sorry to disappoint you but I don't own shares and have just been following the board. As long as this is an OTC micro cap stock and under $5 you have your work cut out for you trying to keep it from being manipulated, but good luck.
1.10 is correct as first Fib support, then .92, then .74.
Fun to watch.
Almost 10m shares traded today, down 6% and still no one here can tell its all distribution from those who accumulated last two weeks and are selling the news. Its a predominantly a short term traders market.
The "oatmeal analogy" makes the point that they could have used many things that meet the safety and tolerance endpoint-like oatmeal. Lots of inert things meet that criterion, so if they meet it with their compound its not a big achievement. Its sort of a given at that point since they often have a good idea of safety from earlier studies. A Ph 2b trial for efficacy is where the compound will start to get attention, although it won't be statistically significant with so few participants. But it will help decide if a ph 3 is warranted.
Don't let it go to your head. You were technically correct on being able to skip trials on occasion but your notion is a long shot.
While you are right about not being obligated to run a ph 2b trial, it better be along FDA guidance and skipping a ph 2b is much more the rule than the exception. They have yet to provide proof of concept and that's part of what a Ph 2b is for. You don't go to an expensive ph 3 without that, especially in a field where there isn't one treatment that has achieved this.
To think that they will be allowed to skip it and go right to a ph 3 is really a stretch and borders on the delusional IMO. You need to get back to reality.
I see. No one can raise an alternate view, show some caution even based on solid precedence in the same field, raise a valid point that softens the buying, right? But please feel free to buy all the shares that you want and I will wait for more solid results.
Good luck.
The bottom line is all Alz treatments have been working off of hypotheses that have never shown proof of concept in trials to date, including 2-73. Its a process of elimination based on educated guesses at this point. Ph 2a is a safety and tolerability trial (so feeding patients oatmeal would meet this endpoint), so we still have to wait for 2b which will begin to have meaningful efficacy data, albeit statistically meaningless. That comes in Ph 3. I would advice investors to reign in any enthusiasm and keep it in line with current progress. Its doing fine so far and there's reason to be hopeful, but past achievements don't always translate into future success. There is a graveyard of more promising Alz treatments already and that fact ought to be respected going forward. Its not a slam dunk but many here talk like it is.
Combination or "cocktail" therapy is one strategy to multi-faceted problems, like AIDS. Sometimes its has more efficacy than a "silver bullet" monotherapy. Its just my opinion on the direction Alzheimer's treatment might lead to in the future, just because its such a difficult condition to cure.
https://en.wikipedia.org/wiki/Combination_therapy
I think it will take a combo of treatments to solve the Alzheimer's problem and I doubt it will be a one treatment cure. Clearing Abeta proteins was thought to be part of it but failed after several companies tried. Several have novel approaches like Neurotrope's Bryostatin which is a PKC activator which can generate new synapses.
I would not dismiss the efforts of much bigger companies with better resources so fast. This field is littered with once very promising treatments that failed at some point, so be wary of being too optimistic. As the Greeks used to warn, "Beware of hubris".
I would temper my enthusiasm on having a cure for Alzheimer's. Many companies have had promising drugs but hit a wall at some point. This disease is very tough to beat and 99% of potential treatments fail in trials.
http://www.foxnews.com/health/2014/07/03/6-percent-alzheimers-disease-drug-trials-fail-experts-find/
http://www.nature.com/nrd/journal/v14/n3/fig_tab/nrd4570_F2.html
Yes, I'm just saying they should take advantage of the pop in price by raising funds when they can under optimal conditions. As an OTC stock I don't have much confidence in the current price holding anywhere near these levels. Strike while the iron's hot.
If they were smart they'd do an offering right here and now. This pop is temporary and mostly traders. Do it Anavex. Do it now.
If I was to add shares to any that I currently hold it would be Opexa. Its shares have gone down to .41 but I think it’s a classic case of investors not wanting to wait around for trial data that's due in 2H 2016.
The new shares don't seem to have been factored into the price yet for some reason. I'd put the fair price at about .70 after this dilution.
I'm really tired of dealing with the risk of OTC companies too. Daily volume is low too. I'd buy some I guess, but not until it comes to me. I continue to monitor it though.